{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:28:54Z","timestamp":1791606534570,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04375-8","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T08:24:26Z","timestamp":1737102266000},"page":"2033-2039","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Intravesical administration of highly concentrated hyaluronic acid and chondroitin sulfate as add-on therapy for chemical cystitis induced by Bacillus Calmette\u2013Gu\u00e9rin (BCG) immunotherapy"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3486-1226","authenticated-orcid":false,"given":"M.","family":"Gubbiotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Rubilotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bacchiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rosadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Serni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Minervini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. Li","family":"Marzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"issue":"1","key":"4375_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O et al (2022) European association of urology guidelines on non- muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 81(1):75\u201394","journal-title":"Eur Urol"},{"issue":"4","key":"4375_CR2","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/bju.13462","volume":"118","author":"N Longo","year":"2016","unstructured":"Longo N, Imbimbo C, Fusco F et al (2016) Complications and quality of life in elderly patients with several comorbidities undergoing cutaneous ureterostomy with single stoma or ileal conduit after radical cystectomy. BJU Int 118(4):521\u2013526","journal-title":"BJU Int"},{"issue":"3","key":"4375_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk M, B\u00f6hle A, Burger M et al (2017) EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 71(3):447\u2013461","journal-title":"Eur Urol"},{"issue":"6","key":"4375_CR4","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/S0022-5347(17)37668-1","volume":"147","author":"S Prescott","year":"1992","unstructured":"Prescott S, James K, Hargreave TB et al (1992) Intravesical Evans strain BCG therapy: Quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 147(6):1636\u20131642","journal-title":"J Urol"},{"issue":"19","key":"4375_CR5","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1001\/jama.2020.17601","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis AT, Lec PM, Chamie K (2020) Bladder cancer. JAMA 324(19):2006","journal-title":"JAMA"},{"issue":"3","key":"4375_CR6","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.eururo.2009.11.023","volume":"57","author":"P Gontero","year":"2010","unstructured":"Gontero P, Bohle A, Malmstrom P-U et al (2010) The role of Bacillus Calmette\u2013Gu\u00e9rin in the treatment of non-muscle-invasive bladder cancer. Eur Urol 57(3):410\u2013429","journal-title":"Eur Urol"},{"issue":"137","key":"4375_CR7","doi-asserted-by":"publisher","first-page":"137ra72","DOI":"10.1126\/scitranslmed.3003586","volume":"4","author":"C Biot","year":"2012","unstructured":"Biot C, Rentsch CA, Gsponer JR et al (2012) Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci Transl Med. 4(137):137ra72","journal-title":"Sci Transl Med."},{"issue":"8","key":"4375_CR8","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1080\/08820139.2022.2118606","volume":"51","author":"DF Ward Grados","year":"2022","unstructured":"Ward Grados DF, Ahmadi H, Griffith TS et al (2022) Immunotherapy for bladder cancer: latest advances and ongoing clinical trials. Immunol Investigat. 51(8):2226\u20132251","journal-title":"Immunol Investigat."},{"issue":"3","key":"4375_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/CAD.0000000000000456","volume":"28","author":"FX Nouhaud","year":"2017","unstructured":"Nouhaud FX, Rigaud J, Saint F et al (2017) Final results of the phase III URO-BCG 4 multicenter study: efficacy and tolerance of one-third dose BCG maintenance in nonmuscle invasive bladder cancer. Anticancer Drugs 28(3):335\u2013340","journal-title":"Anticancer Drugs"},{"issue":"1","key":"4375_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4081\/aiua.2018.1.11","volume":"90","author":"V Imperatore","year":"2018","unstructured":"Imperatore V, Creta M, Di Meo S et al (2018) Intravesical administration of combined hyaluronic acid and chondroitin sulfate can improve symptoms in patients with refractory bacillus Calmette-Guerin-induced chemical cystitis: preliminary experience with one-year follow-up. Arch Ital Urol Androl 90(1):11\u201314","journal-title":"Arch Ital Urol Androl"},{"issue":"5","key":"4375_CR11","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/CAD.0000000000000775","volume":"30","author":"S Poletajew","year":"2019","unstructured":"Poletajew S, Krajewski W, Adamowicz J et al (2019) A systematic review of preventive and therapeutic options for symptoms of cystitis in patients with bladder cancer receiving intravesical bacillus Calmette\u2013Gu\u00e9rin immunotherapy. Anticancer Drugs 30(5):517\u2013522","journal-title":"Anticancer Drugs"},{"issue":"2","key":"4375_CR12","first-page":"145","volume":"62","author":"ML Sommariva","year":"2010","unstructured":"Sommariva ML, Sandri SD, Ceriani V (2010) Efficacy of sodium hyaluronate in the management of chemical and radiation cystitis. Minerva Urol Nefrol 62(2):145\u2013150","journal-title":"Minerva Urol Nefrol"},{"issue":"6","key":"4375_CR13","first-page":"493","volume":"171","author":"JD Lilly","year":"1990","unstructured":"Lilly JD, Parsons CL (1990) Bladder surface glycosaminoglycans is a human epithelial permeability barrier. Surg Gynecol Obstet. 171(6):493\u2013496","journal-title":"Surg Gynecol Obstet."},{"issue":"6","key":"4375_CR14","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.eururo.2007.03.020","volume":"51","author":"C Iavazzo","year":"2007","unstructured":"Iavazzo C, Athanasiou S, Pitsouni E et al (2007) Hyaluronic acid: an effective alternative treatment of interstitial cystitis, recurrent urinary tract infections, and hemorrhagic cystitis? Eur Urol 51(6):1534\u20131540","journal-title":"Eur Urol"},{"issue":"Suppl 3","key":"4375_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1464-410X.2008.07493.x","volume":"101","author":"P Geppetti","year":"2008","unstructured":"Geppetti P, Nassini R, Materazzi S et al (2008) The concept of neurogenic inflammation. BJU Int 101(Suppl 3):2\u20136","journal-title":"BJU Int"},{"issue":"1","key":"4375_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1159\/000345047","volume":"91","author":"E Costantini","year":"2013","unstructured":"Costantini E, Lazzeri M, Pistolesi D et al (2013) Morphological changes of bladder mucosa in patients who underwent instillation with combined sodium hyaluronic acid-chondroitin sulphate (ialuril\u00ae). Urol Int 91(1):81\u201388","journal-title":"Urol Int"},{"issue":"7","key":"4375_CR17","first-page":"328","volume":"58","author":"J Nordling","year":"2008","unstructured":"Nordling J, van Ophoven A (2008) Intravesical glycosaminoglycan replenishment with chondroitin sulphate in chronic forms of cystitis. A multi-national, multi-centre, prospective observational clinical trial. Arzneimittelforschung 58(7):328\u2013335","journal-title":"Arzneimittelforschung"},{"issue":"1","key":"4375_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/BF00182049","volume":"12","author":"CL Parsons","year":"1994","unstructured":"Parsons CL (1994) A model for the function of glycosaminoglycans in the urinary tract. World J Urol 12(1):38\u201342","journal-title":"World J Urol"},{"issue":"6","key":"4375_CR19","doi-asserted-by":"publisher","first-page":"e0218475","DOI":"10.1371\/journal.pone.0218475","volume":"14","author":"A Stellavato","year":"2019","unstructured":"Stellavato A, Pirozzi AVA, Diana P et al (2019) Hyaluronic acid and chondroitin sulfate, alone or in combination, efficiently counteract induced bladder cell damage and inflammation. PLoS ONE 14(6):e0218475","journal-title":"PLoS ONE"},{"issue":"6","key":"4375_CR20","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.eursup.2011.06.001","volume":"10","author":"PF Bassi","year":"2011","unstructured":"Bassi PF, Costantini E, Foley S et al (2011) Glycosaminoglycan therapy for bladder diseases: emerging new treatments. Eur Urol Suppl 10(6):451\u2013459","journal-title":"Eur Urol Suppl"},{"issue":"157","key":"4375_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.carbpol.2016.07.125","volume":"10","author":"A D\u2019Agostino","year":"2017","unstructured":"D\u2019Agostino A, Stellavato A, Corsuto L et al (2017) Is molecular size a discriminating factor in hyaluronan interaction with human cells? Carbohydr Polym 10(157):21\u201330","journal-title":"Carbohydr Polym"},{"key":"4375_CR22","first-page":"S0302-2838(24)0","volume":"17","author":"P Gontero","year":"2024","unstructured":"Gontero P, Birtle A, Capoun O et al (2024) European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)- a summary of the 2024 guidelines update. Eur Urol 17:S0302-2838(24)02514\u20134","journal-title":"Eur Urol"},{"issue":"2S","key":"4375_CR23","first-page":"189","volume":"97","author":"MJ Barry","year":"2017","unstructured":"Barry MJ, Fowler FJ Jr, O\u2019Leary MP et al (2017) The American urological association symptom index for benign prostatic hyperplasia. J Urol 97(2S):189\u2013197","journal-title":"J Urol"},{"issue":"1","key":"4375_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1590\/s1677-5538.ibju.2018.0496","volume":"45","author":"M Els","year":"2019","unstructured":"Els M, Heins C, van der Merwe A et al (2019) Prospective comparison of the novel visual prostate symptom score (VPSS) versus the international prostate symptom score (IPSS), and assessment of patient pain perception with regard to transrectal ultrasound guided prostate biopsy. Int Braz J Urol 45(1):137\u2013144","journal-title":"Int Braz J Urol"},{"key":"4375_CR25","unstructured":"Y. Aso, C. Abbou, P. Abrams, et al. (1996) Clinical research criteria, in Cockett ATK, Khoury S, Aso Y, et al (Eds): Proceedings of the Third International Consultation on Benign Prostatic Hy- perplasia (BPH). Channel Islands, Scientific Communications International. pp 461-468."},{"issue":"1","key":"4375_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"M Brausi","year":"2014","unstructured":"Brausi M, Oddens J, Sylvester R et al (2014) Side Effects of Bacillus Calmette\u2013Gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol 65(1):69\u201376","journal-title":"Eur Urol"},{"issue":"3","key":"4375_CR27","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.juro.2006.04.104","volume":"176","author":"M Colombel","year":"2006","unstructured":"Colombel M, Saint F, Chopin D et al (2006) The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 176(3):935\u2013939","journal-title":"J Urol"}],"updated-by":[{"DOI":"10.1007\/s11255-025-04404-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000}}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04375-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04375-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04375-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T08:16:40Z","timestamp":1749889000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04375-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["4375"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04375-8","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11255-025-04404-6","URL":"https:\/\/doi.org\/10.1007\/s11255-025-04404-6","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical standards were performed according to the 1964 Declaration of Helsinki and its later amendments. Local institutional review board and ethics committee (A.O.U.I Verona, dept. of Urology, University of Verona) approvals were obtained. This work was performed under the supervision of the University of Verona Institutional review Board following the Declaration of Helsinki and all participants were consented for the study. Local Ethics Committee for Clinical Trials (CESC) determined that the approval for this investigation was unnecessary, since it only involved standard clinical practice. The study is not a clinical trial; therefore, it is not reported the registration number.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was acquired from all patients enrolled before inclusion in the study. There is no material reproduced from other sources.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}